当代医学
噹代醫學
당대의학
CHINA CONTEMPORARY MEDICINE
2014年
16期
124-126
,共3页
依那普利叶酸片%冠心病%同型半胱氨酸%心功能
依那普利葉痠片%冠心病%同型半胱氨痠%心功能
의나보리협산편%관심병%동형반광안산%심공능
Enalapril-folic acid tablets%Coronary heart disease%Homocysteine%Cardiac function
目的：观察依那普利叶酸片对冠心病患者同型半胱氨酸及心功能的影响。方法选取2013年1月～2013年11月广东省阳江市人民医院收治的入院时高度怀疑冠心病、且愿意接受冠脉造影（CAG）检查、自愿参与研究的患者为研究对象。对入选患者行CAG检查，选取CAG检查正常者作为空白对照组（A组，n=50），将CAG检查诊断为冠心病者随机分为马来酸依那普利叶酸片治疗组（B组，n=50）及依那普利片治疗组(C组，n=50)。A组服用安慰剂，B组服用马来酸依那普利叶酸片，C组服用依那普利片，所有冠心病患者常规服用抗血小板药物、调脂药物、硝酸酯类药物、β-受体阻滞剂，合并高血压者服用降压药，合并糖尿病者服用降糖药物，对所有患者在入院第2 d及服药后3个月、6个月测量血Hcy、肝肾功能及心功能。结果 B、C两组同型半胱氨酸水平明显高于A组（P＜0.05），心功能差于A组（P＜0.05），B组患者服药6个月后同型半胱氨酸水平明显下降（P＜0.05），心功能显著改善（P＜0.05），C组患者服药后同型半胱氨酸水平无明显变化，心功能较未服药时明显改善（P＜0.05），但效果劣于B组服药6个月后。所有患者服药半年后肝肾功能无明显变化。结论依那普利叶酸片与依那普利片对比，可明显降低冠心病患者同型半胱氨酸水平，改善其心功能。
目的：觀察依那普利葉痠片對冠心病患者同型半胱氨痠及心功能的影響。方法選取2013年1月～2013年11月廣東省暘江市人民醫院收治的入院時高度懷疑冠心病、且願意接受冠脈造影（CAG）檢查、自願參與研究的患者為研究對象。對入選患者行CAG檢查，選取CAG檢查正常者作為空白對照組（A組，n=50），將CAG檢查診斷為冠心病者隨機分為馬來痠依那普利葉痠片治療組（B組，n=50）及依那普利片治療組(C組，n=50)。A組服用安慰劑，B組服用馬來痠依那普利葉痠片，C組服用依那普利片，所有冠心病患者常規服用抗血小闆藥物、調脂藥物、硝痠酯類藥物、β-受體阻滯劑，閤併高血壓者服用降壓藥，閤併糖尿病者服用降糖藥物，對所有患者在入院第2 d及服藥後3箇月、6箇月測量血Hcy、肝腎功能及心功能。結果 B、C兩組同型半胱氨痠水平明顯高于A組（P＜0.05），心功能差于A組（P＜0.05），B組患者服藥6箇月後同型半胱氨痠水平明顯下降（P＜0.05），心功能顯著改善（P＜0.05），C組患者服藥後同型半胱氨痠水平無明顯變化，心功能較未服藥時明顯改善（P＜0.05），但效果劣于B組服藥6箇月後。所有患者服藥半年後肝腎功能無明顯變化。結論依那普利葉痠片與依那普利片對比，可明顯降低冠心病患者同型半胱氨痠水平，改善其心功能。
목적：관찰의나보리협산편대관심병환자동형반광안산급심공능적영향。방법선취2013년1월～2013년11월광동성양강시인민의원수치적입원시고도부의관심병、차원의접수관맥조영（CAG）검사、자원삼여연구적환자위연구대상。대입선환자행CAG검사，선취CAG검사정상자작위공백대조조（A조，n=50），장CAG검사진단위관심병자수궤분위마래산의나보리협산편치료조（B조，n=50）급의나보리편치료조(C조，n=50)。A조복용안위제，B조복용마래산의나보리협산편，C조복용의나보리편，소유관심병환자상규복용항혈소판약물、조지약물、초산지류약물、β-수체조체제，합병고혈압자복용강압약，합병당뇨병자복용강당약물，대소유환자재입원제2 d급복약후3개월、6개월측량혈Hcy、간신공능급심공능。결과 B、C량조동형반광안산수평명현고우A조（P＜0.05），심공능차우A조（P＜0.05），B조환자복약6개월후동형반광안산수평명현하강（P＜0.05），심공능현저개선（P＜0.05），C조환자복약후동형반광안산수평무명현변화，심공능교미복약시명현개선（P＜0.05），단효과렬우B조복약6개월후。소유환자복약반년후간신공능무명현변화。결론의나보리협산편여의나보리편대비，가명현강저관심병환자동형반광안산수평，개선기심공능。
Objective To observe the therapeutic eficacy of enalapril-folic acid tablets on coronary heart disease patients’s homocysteine and cardiac function. Methods From Jam 2013 to Nov. 2013, 150 patients from our hospital’s inpatient department were included in this research, all patients were highly suspected coronary heart disease, and willing to accept the coronary angiography (CAG) examination. According to the CAG examination, the patients were divided into CAG normal group (group A) and coronary heart disease group, the patients of coronary heart disease group were randomly divided into enalapril-folic acid tablets treatment group (group B) and enalapril treatment group (group C), there are 50 cases in each group. Group A received placebo, B group was treated with enalapril-folic acid tablets, C group was treated with enalapril. Patients with coronary heart disease taked antiplatelet drugs, Lipid-lowering drugs, nitrates, B receptor blockers, with hypertension taking blood pressure medication, with diabetes mellitus taking glucose-lowering drugs. All patients were measured liver function、kidney function and cardiac function on the second day after admission and after treatment for 3 months, 6 months. Results To compare with group A,there were higher levels of Hcy and worse cardiac function of group B and group C (P<0.05);After 6 months treatment ,the Hcy was lower and the cardiac function was promoted in group B (P<0.05). There was no change of Hcy in group C after drug treatment, but the cardiac function was promoted after drug treatment (P<0.05). liver and kidney function had no obvious change after 6 months drug treatment in each group. Conclusion Enalapril-folic acid tablets had the better effect than enalapril in lowing Hcy and promoting cardiac function of coronary heart disease patients.
